



## 1<sup>st</sup> VIRTUAL SIBBM Covid-19 Seminar

### Molecular Biology at the times of SARS-CoV-2 epidemics: the key contributions of Molecular Biology to the understanding and therapy of Covid-19

2 JULY 2020

ON ZOOM

14:00-14:20 **Introduction**

**Valeria Poli** – University of Turin

Testing, Tracing, Treating: the unique contributions of Molecular Biology not only to the development of SARS-CoV-2 therapies, but also to diagnosis

14:20-14:50 **Sachdev Sidhu** - University of Toronto

COVID-19 Biologic Therapeutic Development in Real Time

14:50-15:20 **Pier Paolo Pandolfi** - University of Turin

Targeted therapies for Covid-19 and other RNA viruses

15:20-15:50 **Giuseppe Novelli** - Tor Vergata University of Rome

COVID-19: Genetics, is it the answer?

15:50-16:20 **Coffee break**

16:20-16:50 **Federica Facciotti** - European Institute of Oncology, Milan

Serological tests for SARS-Cov2 Antibodies detection: the IEO experience

16:50-17:05 **Barbara Illi** - National Research Council, Rome

SIBBM-Zanichelli Covid-19 web resource presenting molecular, genomic, epidemiological and social sciences approaches towards the understanding and solution of the epidemics.

17:10-17:40 **Graziano Pesole** - National Research Council, Bari and University of Bari

Comparative and evolutionary genomics of SARS-Cov-2

17:40-18:10 **Luigi Aurisicchio** - Takis S.r.l., Rome

Generation of recombinant viral vectors for vaccine and gene therapy applications

18:10-18:30 **Conclusions**

More information and  
the zoom link at  
<https://www.sibbm.org>



@sibbm2

## Speakers

### **Sachdev Sidhu –**

The Donnelly Centre,  
University of Toronto  
160 College Street, Room 816  
Toronto, Ontario Canada M5S 3E1  
[sachdev.sidhu@utoronto.ca](mailto:sachdev.sidhu@utoronto.ca)

### **Pier Paolo Pandolfi –**

Department of Molecular Biotechnology and Health Sciences  
Molecular Biotechnology Center,  
University of Turin  
Via Nizza 52, 10126 - Turin, Italy  
[pierpaolo.pandolfiderinaldis@unito.it](mailto:pierpaolo.pandolfiderinaldis@unito.it)

### **Giuseppe Novelli –**

Laboratory of Medical Genetics  
Tor Vergata University of Rome  
V.le Oxford 81, 00133 - Rome, Italy  
[novelli@med.uniroma2.it](mailto:novelli@med.uniroma2.it)

### **Federica Facciotti –**

Mucosal Immunology  
European Institute of Oncology  
Via Adamello 16, 20139 - Milan, Italy  
[federica.facciotti@ieo.it](mailto:federica.facciotti@ieo.it)

### **Barbara Illi –**

Institute of Molecular Biology and Pathology  
National Research Council  
Department of Biology and Biotechnology "Charles Darwin",  
Sapienza University of Rome  
[barbara.illi@uniroma1.it](mailto:barbara.illi@uniroma1.it)

### **Graziano Pesole –**

Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies  
National Research Council, Bari, Italy  
Department of Biosciences, Biotechnologies and Biopharmaceutics,  
University of Bari "A. Moro",  
via Amendola 165/A, 70125 - Bari, Italy  
[graziano.pesole@uniba.it](mailto:graziano.pesole@uniba.it)

### **Luigi Aurisicchio –**

Chief Executive and Scientific Officer,  
Takis S.r.l.  
Via Castel Romano, 100, 00128 - Rome, Italy  
[aurisicchio@takisbiotech.it](mailto:aurisicchio@takisbiotech.it)